Literature DB >> 25809767

Fluoroquinolone-resistant tuberculosis: implications in settings with weak healthcare systems.

Kauser Jabeen1, Sadia Shakoor1, Rumina Hasan2.   

Abstract

Fluoroquinolones (FQ) play an essential role in the treatment and control of multidrug-resistant tuberculosis (MDR-TB). They are also being evaluated as part of newer regimens under development for drug-sensitive TB. As newer FQ-based regimens are explored, knowledge of FQ resistance data from high TB burden countries becomes essential. We examine available FQ resistance data from high TB burden countries and demonstrate the need for comprehensive surveys to evaluate FQ resistance in these countries. The factors driving FQ resistance in such conditions and the cost of such resistance to weak healthcare systems are discussed. The need for a comprehensive policy for addressing the issue of FQ resistance is highlighted.
Copyright © 2015 The Authors. Published by Elsevier Ltd.. All rights reserved.

Entities:  

Keywords:  Drug-resistant tuberculosis; Fluoroquinolone resistance; Health systems; Tuberculosis

Mesh：

Substances：

Year:  2015        PMID： 25809767     DOI： 10.1016/j.ijid.2015.01.006

Source DB:  PubMed          Journal:  Int J Infect Dis        ISSN： 1201-9712            Impact factor:   3.623


  11 in total

1.  Limited Effect of Later-Generation Fluoroquinolones in the Treatment of Ofloxacin-Resistant and Moxifloxacin-Susceptible Multidrug-Resistant Tuberculosis.

Authors:  Hyun Lee; Soohyun Ahn; Na Young Hwang; Kyeongman Jeon; O Jung Kwon; Hee Jae Huh; Nam Yong Lee; Chang-Ki Kim; Won-Jung Koh
Journal:  Antimicrob Agents Chemother       Date:  2018-01-25       Impact factor: 5.191

2.  Clinical Impact of Rapid Drug Susceptibility Testing to Accompany Fluoroquinolone-Containing Universal Tuberculosis Regimens: A Markov Model.

Authors:  Emily A Kendall; Shelly Malhotra; Sarah Cook-Scalise; David W Dowdy; Claudia M Denkinger
Journal:  Clin Infect Dis       Date:  2020-12-31       Impact factor: 9.079

3.  Sequence Analysis of Fluoroquinolone Resistance-Associated Genes gyrA and gyrB in Clinical Mycobacterium tuberculosis Isolates from Patients Suspected of Having Multidrug-Resistant Tuberculosis in New Delhi, India.

Authors:  Ritu Singhal; Paul R Reynolds; Jamie L Marola; L Elaine Epperson; Jyoti Arora; Rohit Sarin; Vithal Prasad Myneedu; Michael Strong; Max Salfinger
Journal:  J Clin Microbiol       Date:  2016-06-22       Impact factor: 5.948

4.  Predicting the Outcomes of New Short-Course Regimens for Multidrug-Resistant Tuberculosis Using Intrahost and Pharmacokinetic-Pharmacodynamic Modeling.

Authors:  Tan N Doan; Pengxing Cao; Theophilus I Emeto; James M McCaw; Emma S McBryde
Journal:  Antimicrob Agents Chemother       Date:  2018-11-26       Impact factor: 5.191

5.  Hospital antibiotic prescribing patterns in adult patients according to the WHO Access, Watch and Reserve classification (AWaRe): results from a worldwide point prevalence survey in 69 countries.

Authors:  Ines Pauwels; Ann Versporten; Nico Drapier; Erika Vlieghe; Herman Goossens
Journal:  J Antimicrob Chemother       Date:  2021-05-12       Impact factor: 5.790

6.  Interplay of the Quality of Ciprofloxacin and Antibiotic Resistance in Developing Countries.

Authors:  Deepali Sharma; Rahul P Patel; Syed Tabish R Zaidi; Md Moklesur Rahman Sarker; Qi Ying Lean; Long C Ming
Journal:  Front Pharmacol       Date:  2017-08-21       Impact factor: 5.810

7.  Age-stratified anti-tuberculosis drug resistance profiles in South Korea: a multicenter retrospective study.

Authors:  Eung Gu Lee; Jinsoo Min; Ji Young Kang; Sung Kyoung Kim; Jin Woo Kim; Yong Hyun Kim; Hyoung Kyu Yoon; Sang Haak Lee; Hyung Woo Kim; Ju Sang Kim
Journal:  BMC Infect Dis       Date:  2020-06-23       Impact factor: 3.090

8.  Elucidating the Antimycobacterial Mechanism of Action of Ciprofloxacin Using Metabolomics.

Authors:  Kirsten E Knoll; Zander Lindeque; Adetomiwa A Adeniji; Carel B Oosthuizen; Namrita Lall; Du Toit Loots
Journal:  Microorganisms       Date:  2021-05-28

Review 9.  Management of multidrug-resistant TB: novel treatments and their expansion to low resource settings.

Authors:  Derek J Sloan; Joseph M Lewis
Journal:  Trans R Soc Trop Med Hyg       Date:  2016-03       Impact factor: 2.184

10.  Development of a risk score for prediction of poor treatment outcomes among patients with multidrug-resistant tuberculosis.

Authors:  Kefyalew Addis Alene; Kerri Viney; Darren J Gray; Emma S McBryde; Zuhui Xu; Archie C A Clements
Journal:  PLoS One       Date:  2020-01-03       Impact factor: 3.240
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.